Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
05 9월 2023 - 9:30PM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines, today announced the appointment of
Dorothy Clarke to its Board of Directors.
“We are delighted to welcome Dorothy to our Board,” said Matt
Angel, Ph.D., Chief Executive Officer and President of Eterna.
“Dorothy’s extensive regulatory and legal expertise and experience
as a Fortune 100 executive in the biopharmaceutical and healthcare
sector will be invaluable as we continue to execute on our business
and partnering strategies to deliver on the promise of mRNA cell
engineering.”
Ms. Clarke added, “I believe Eterna’s mRNA cell engineering
platform holds significant potential for collaborative
opportunities, and look forward to working with the leadership team
and my fellow Board members to advance Eterna’s growth and
corporate strategy.”
Ms. Clarke held various leadership positions at Johnson &
Johnson over 20 years across the company’s pharmaceutical, medical
devices & diagnostics, and consumer sectors. She initially
joined the Law Department, serving as Assistant General Counsel in
the Regulatory and Medical Devices Groups, and later served as Vice
President, Regulatory Affairs; Vice President, Chief Privacy
Officer; Chief Compliance Officer for Medical Devices &
Diagnostics, and most recently Vice President, Research &
Development, Innovation and Business Development Compliance. During
her tenure at Johnson & Johnson, Ms. Clarke led compliance,
regulatory and data protection functions, addressed regulatory
inquiries and investigations, and conducted due diligence for
numerous acquisitions. Prior to Johnson & Johnson, she was an
attorney at the law firms Reinhart Boerner Van Deuren, S.C., and
Fox, Bennett & Turner, where she represented pharmaceutical
companies and patient advocacy groups, as well as healthcare
organizations and professionals including hospitals, nursing homes
and physicians. Ms. Clarke holds a J.D. from New York University
School of Law.
About Eterna Therapeutics Inc.Eterna
Therapeutics is a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines. Eterna has in-licensed a portfolio
of over 130 patents covering key mRNA cell engineering
technologies, including technologies for mRNA cell reprogramming,
mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing
proteins, and the ToRNAdo™ mRNA delivery system from Factor
Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are trademarks of
Factor Bioscience. For more information, please visit
www.eternatx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are intended
to be covered by the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are any statements that are not statements of historical
fact and may be identified by terminology such as “believe,”
“could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,”
“potential,” “project,” “will” or other similar words and the
negatives of such words. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those stated or implied in any
forward-looking statement as a result of various factors,
including, but not limited to, uncertainties related to: (i) the
evolution of Eterna’s business model into a platform company
focused on mRNA, induced pluripotent stem (iPS) cell and gene
editing technologies; (ii) Eterna’s ability to successfully,
cost-effectively and efficiently develop its technology and
products; (iii) Eterna’s ability to successfully commence clinical
trials of any products on a timely basis or at all; (iv) Eterna’s
ability to successfully fund and manage the growth of its
development activities; and (v) Eterna’s ability to obtain
regulatory approvals of its products for commercialization. You
should not rely upon forward-looking statements as predictions of
future events. The forward-looking statements made in this
communication speak only as of the date on which they were made,
and Eterna does not undertake any obligation to update the
forward-looking statements contained herein to reflect events that
occur or circumstances that exist after the date hereof, except as
required by applicable law. Factors that may cause Eterna’s actual
results to differ from those expressed or implied in
forward-looking statements contained in this press release are more
fully disclosed in Eterna’s periodic public filings with the U.S.
Securities and Exchange Commission, particularly under the heading
“Risk Factors” in Eterna’s Annual Report on Form 10-K for the year
ended December 31, 2022, as well as under similar headings in
Eterna’s subsequently filed Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K.
Investor Relations
Contact:investors@eternatx.com
Media Contact:EternaPR@westwicke.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4072f2f1-de68-4422-9cb2-2423b7e665da
Eterna Therapeutics (NASDAQ:ERNA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Eterna Therapeutics (NASDAQ:ERNA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024